TalkMed Group Ltd. (SG:5G3) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TalkMed Group Ltd. has announced its subsidiary BioCell Innovations Pte. Ltd.’s non-binding MOU with Thermo Fisher Scientific to improve the manufacturing of CAR-T immunotherapies in the Asia-Pacific. This collaboration aims to accelerate the development of cell therapies by leveraging BioCell’s vector design expertise and Thermo Fisher’s cell processing technologies. The company will keep its shareholders informed about significant future developments.
For further insights into SG:5G3 stock, check out TipRanks’ Stock Analysis page.